We are live on ! Find out more
CYT

Cyteir Therapeutics, Inc. Common Stock

Delisted

CYT was delisted on the 15th of March, 2024.

52 hedge funds and large institutions have $83.8M invested in Cyteir Therapeutics, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 21 increasing their positions, 9 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

133% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 9

44% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 9

8% more funds holding

Funds holding: 4852 (+4)

50% less funds holding in top 10

Funds holding in top 10: 21 (-1)

67% less capital invested

Capital invested by funds: $253M → $83.8M (-$170M)

Holders
52
Holders Change
+4
Holders Change %
+8.33%
% of All Funds
0.82%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
13
Increased
21
Reduced
9
Closed
9
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
ACP
51
Acuta Capital Partners
California
-$4.46M -391,974 Closed
ABG
52
Ally Bridge Group
New York
-$3.63M -319,538 Closed
SI
53
Sofinnova Investments
California
-$2.04M -179,450 Closed
SFM
54
Sphera Funds Management
Israel
-$1.12M -98,860 Closed
GTCM
55
Gyon Technologies Capital Management
New Jersey
-$254K -22,345 Closed
Jane Street
56
Jane Street
New York
-$180K -15,843 Closed
E
57
Ergoteles
New York
-$152K -13,355 Closed
HNWAG
58
High Net Worth Advisory Group
Florida
-$6K -500 Closed
SOW
59
State of Wyoming
Wyoming
-$1K -44 Closed
MAM
60
Meeder Asset Management
Ohio
+$17 +3 New

CYT Hedge Fund Activity: Q1 2022 in Review

52 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Cyteir Therapeutics, Inc. Common Stock (CYT) for Q1 2022, worth a combined $83.8M — down 67% from $253M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new CYT positions and 9 closed out — a net gain of 4 holders — while 21 added to existing stakes and 9 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $2.57M. The largest seller was Acuta Capital Partners, exiting entirely with an estimated $4.46M sold.

  • 52 institutional investors held Cyteir Therapeutics, Inc. Common Stock (CYT) as of Q1 2022, up from 48 in Q4 2021.
  • Funds reported $83.8M of Cyteir Therapeutics, Inc. Common Stock stock for Q1 2022, down 67% quarter-over-quarter.
  • 13 funds opened new Cyteir Therapeutics, Inc. Common Stock positions in Q1 2022 and 9 closed out, a net change of +4 holders.
  • The largest Cyteir Therapeutics, Inc. Common Stock buyer in Q1 2022 was Fidelity Investments, an estimated $2.57M added.
  • The largest Cyteir Therapeutics, Inc. Common Stock seller in Q1 2022 was Acuta Capital Partners, an estimated $4.46M sold.

Based on aggregated 13F filings for Q1 2022.